Man Group’s Prelude Therapeutics PRLD Stock Holding History

Man Group’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20,994	Closed	-$128K	–	1916
2022 Q4	$127K	Buy	+20,994	New	+$135K	﹤0.01%	1873

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group's PRLD Position: Q1 2023 in Review

Man Group sold out of Prelude Therapeutics (PRLD) in Q1 2023, closing a stake of 20,994 shares — an estimated $128K sold.

Man Group first reported a position in PRLD in Q4 2022 and held it in 1 quarter. The position peaked at $127K in Q4 2022. 54 funds tracked by Wall St. Rank hold PRLD as of Q1 2023.

Man Group reported no remaining Prelude Therapeutics position as of Q1 2023 after selling out during the quarter.
Man Group sold 20,994 Prelude Therapeutics shares in Q1 2023, an estimated $128K.
Man Group first reported a position in Prelude Therapeutics in Q4 2022 and held it in 1 quarter.
Man Group's Prelude Therapeutics position peaked at $127K in Q4 2022.
54 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.